Upfront Briefing
Heavy AAN day. Roche scored twice — full fenebrutinib Phase 3 data in RMS (51–59% relapse reductions, but a 7-vs-1 mortality imbalance that will shape the label debate) and a clean 68% win for ENSPRYNG in MOGAD (the first-ever positive pivotal). Merck gave some back: LITESPARK-012 failed, lopping first-line optionality off Welireg and opening the 1L RCC door wider for Arcus and Exelixis.
On the regulatory tape: Sanofi's Tzield expands to kids as young as 1 in the U.S.; Ipsen's Ojemda clears the EU for relapsed pLGG (and becomes the first asset to run the EU JCA). On the private-market tape: Ray Therapeutics printed a crossover-heavy $125M Series B and Sage alum Jeff Jonas launched Tortugas Neuroscience with $106M.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,064.0 |
(0.6%) |
+2.7% |
| Nasdaq 100 |
26,479.5 |
(0.4%) |
+4.6% |
| Russell 2000 |
2,765.0 |
(1.0%) |
+2.5% |
| Healthcare (XLV) |
145.9 |
(1.0%) |
(7.4%) |
| Biotech (XBI) |
136.4 |
(1.0%) |
+6.4% |
| Nasdaq Biotech (NBI) |
6,046.5 |
(0.9%) |
+2.0% |
| Clinical Trials (BBC) |
47.1 |
(1.4%) |
+11.1% |
|
- Broad tape took a risk-off breather as crude jumped ~2.4% on a prolonged Strait of Hormuz closure and the end of the Iran ceasefire loomed overnight; Treasury yields firmed after stronger-than-expected core retail sales and ADP prints.
- Biotech beta underperformed (XBI (1.0%), NBI (0.9%)) versus the S&P 500 ((0.6%)) — a mild bid fade after a sharp 1-month rally (XBI up ~75% off April 2025 lows) with profit-taking concentrated in higher-beta names.
- Standout mover: Clinical Trials (BBC) (1.4%), the worst-performing basket on the day; still +11.1% YTD.
- Market data: U.S. close Tue 21-Apr-2026.
The Big 3
|
1
|
Sanofi's Tzield wins US nod to delay stage 3 T1D in kids
|
- FDA approved Sanofi's supplemental BLA for Tzield (teplizumab), dropping the minimum age from 8 to 1 year to delay onset of stage 3 T1D in stage 2 patients. Decision supported by one-year data from the 23-patient Phase 4 PETITE-T1D study.
- Why it matters: Younger-age expansion doesn't move the needle commercially by itself (23-pt Phase 4 in a niche population), but it reinforces the disease-modifying narrative at the earliest possible intervention point — and keeps Tzield relevant as screening expands. The bigger catalyst is the separate sBLA under review to delay stage 3→stage 4 progression in 8+yo patients already diagnosed; that's the lifecycle lever that could actually reset peak sales.
- Source: PR
- More: PR (FR)
|
|
2
|
Merck/Eisai LITESPARK-012 fails in 1L kidney cancer; MRK off 3.7%
|
- Phase 3 LITESPARK-012 (n=1,688) missed both dual primary endpoints (PFS and OS) at interim — neither the Welireg + Keytruda + Lenvima triplet nor the MK-1308A + Lenvima arm beat the Keytruda + Lenvima control in 1L clear cell RCC. Safety was consistent with prior data. MRK traded off ~3.7%.
- Why it matters: This effectively ends Welireg's 1L RCC optionality — Bloomberg Intelligence cut 2030 Welireg sales estimates by ~$300M (~13%), though the hit to Merck overall is <1% of sales. The bigger read-through is for the competitive set: analysts (Mizuho, Cantor) flagged the miss as a clear opening for Arcus' casdatifan (differentiated HIF-2α, no TKI combo toxicity) and Exelixis' zanzalintinib in the 1L setting. LITESPARK-011 (Welireg + Lenvima in relapsed/refractory RCC) is unaffected, with a PDUFA of Oct 4, 2026.
- Source: BioPharma Dive
- More: BioSpace
|
|
3
|
Roche fenebrutinib AAN full data: efficacy clean, mortality imbalance flagged
|
- Full FENhance 1 + 2 data at AAN 2026: fenebrutinib cut ARR 51.1% (FENhance 1) and 58.5% (FENhance 2) vs. teriflunomide (p<0.001 / <0.0001) over 96 weeks. MRI secondaries crushed it (70.7%/77.6% T1-Gd+ reduction; 76.0%/82.5% T2 reduction). Disability progression trended favorable but was not statistically significant (HR 0.80 / 0.87).
- Why it matters: Efficacy is best-in-class oral for RMS — but approvability is now the investor debate. Liver enzyme elevations were actually comparable to teriflunomide (one Hy's Law case in each arm, both resolved), so the liver narrative is softer than headlines suggest. The real overhang is the mortality imbalance: 7 deaths on fenebrutinib vs. 1 on teriflunomide (0.9% vs. 0.1%) across both studies, causes heterogeneous. Jefferies' Leuchten has openly questioned whether the profile clears FDA's bar given last year's tolebrutinib rejection. Watch for label restrictions / REMS if approved — and the PPMS franchise lever (FENtrepid non-inferior to Ocrevus) as an additional optionality case.
- Source: Endpoints
- More: PR
|
Everything Else that broke
- Roche's ENSPRYNG (satralizumab) hits in MOGAD Phase 3 METEOROID — 68% reduction in relapse risk vs. placebo; first-ever positive pivotal in this rare CNS autoimmune disease (no approved therapies today). Submissions planned globally. — PR
- Ipsen's Ojemda (tovorafenib) approved in EU for relapsed/refractory pediatric low-grade glioma in patients 6mo+ with BRAF fusion/rearrangement or V600 mutation. FIREFLY-1 showed 71% ORR (RANO-HGG) / 53% ORR (RAPNO-LGG), 18-mo median DoR. First medicine to run through the EU's new Joint Clinical Assessment (JCA) process — positive structural read-through for other ex-U.S. launches. — PR
- Medicare indefinitely delays pilot to cover weight-loss drugs. — Endpoints
- Key GOP senators push back on Trump plan to cut NIH and reorganize HHS. — STAT
- Samsung Biologics reports Q1 2026 financial results. — PR
- Kyverna to seek FDA approval for stiff person syndrome cell therapy. — STAT
- Revolution Medicines posts more KRAS data; teases novel class. — STAT
- Sanofi updates US regulatory submission for Sarclisa subcutaneous. — PR
- Dayspring Pharma says Phase 2 CG2001 foam hit endpoint in AGA. — PR
- Ractigen posts Phase 1 SOD1-ALS data with 81% NfL drop. — PR
- BioMarin announces board leadership transition. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Curiox signs master software license for enterprise Pluto Code. — PR
Venture Capital
- Ray Therapeutics closed an upsized/oversubscribed $125M Series B for optogenetic vision restoration (lead RTx-015 in retinitis pigmentosa, RMAT designated). Led by Janus Henderson; new investors Adage, Franklin Templeton, Invus, Marshall Wace; existing 4BIO Capital, Deerfield, Merck MRL Ventures, Norwest, Novo Holdings, Platanus. Crossover-heavy syndicate, late-stage setup. — PR
- Tortugas Neuroscience launched with $106M seed + Series A; neurology pipeline in-licensed from Eisai and Jiangsu Hansoh (lead programs in schizophrenia and tinnitus, also focal epilepsy). Seed led by Cure Ventures; Series A co-led by Cure Ventures, The Column Group, and AN Venture Partners. Run by Sage Therapeutics alumni Jeff Jonas (CEO) and Al Robichaud (R&D). — PR
IPOs / Follow-Ons
- Nektar prices upsized $325M public offering. — PR
|
